L M Krug

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 104:2149-55. 2005
  2. ncbi request reprint An overview of chemotherapy for mesothelioma
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 19:1117-36, vii. 2005
  3. ncbi request reprint Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid
    Lee M Krug
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Lung Cancer 7:257-61. 2006
  4. ncbi request reprint Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 103:2128-31. 2005
  5. ncbi request reprint Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin
    Lee M Krug
    Thoracic Oncology Service, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6094-100. 2004
  6. ncbi request reprint Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 2:317-20. 2007
  7. ncbi request reprint Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10021, USA
    J Thorac Oncol 2:947-52. 2007
  8. pmc Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma
    Lee M Krug
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:3007-13. 2009
  9. ncbi request reprint 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University New York, New York 10021, USA
    Clin Cancer Res 9:2072-8. 2003
  10. doi request reprint WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
    Lee M Krug
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY, 10065, USA
    Cancer Immunol Immunother 59:1467-79. 2010

Detail Information

Publications43

  1. ncbi request reprint Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 104:2149-55. 2005
    ..In the current study, the authors combined trastuzumab with weekly taxanes in an attempt to improve outcomes over standard chemotherapy in patients with advanced NSCLC...
  2. ncbi request reprint An overview of chemotherapy for mesothelioma
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 19:1117-36, vii. 2005
    ..The role of treatment in various disease settings and the difficulty in assessing the benefit of that therapy is discussed. Finally, an update is provided on novel therapeutics being testing in mesothelioma...
  3. ncbi request reprint Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid
    Lee M Krug
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Lung Cancer 7:257-61. 2006
    ....
  4. ncbi request reprint Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 103:2128-31. 2005
    ..The authors conducted a Phase II single-institution study of imatinib in patients with recurrent SCLC whose tumor specimens expressed c-kit protein...
  5. ncbi request reprint Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin
    Lee M Krug
    Thoracic Oncology Service, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6094-100. 2004
    ..A prior clinical study demonstrated the potent immunogenicity of fucosyl GM-1 derived from bovine thyroid gland, conjugated to keyhole limpet hemocyanin (KLH) and administered with QS-21 adjuvant...
  6. ncbi request reprint Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 2:317-20. 2007
    ..In mesothelioma cell lines and xenografts, pralatrexate demonstrated significant antitumor activity...
  7. ncbi request reprint Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10021, USA
    J Thorac Oncol 2:947-52. 2007
    ..A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies...
  8. pmc Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma
    Lee M Krug
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:3007-13. 2009
    ....
  9. ncbi request reprint 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University New York, New York 10021, USA
    Clin Cancer Res 9:2072-8. 2003
    ..The recommended Phase II dose was 150 mg/m(2) i.v. every 2 weeks. Responses observed in patients with non-small cell lung cancer (NSCLC) in the Phase I trial prompted this Phase II trial...
  10. doi request reprint WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
    Lee M Krug
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY, 10065, USA
    Cancer Immunol Immunother 59:1467-79. 2010
    ..We tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II peptides in patients with thoracic neoplasms expressing WT1...
  11. pmc Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci
    Lee M Krug
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY 10065, USA
    Cancer Immunol Immunother 61:9-18. 2012
    ..The objectives of the current trial were to establish the lowest optimal dose and to confirm the safety of the induction of antibodies against polySA with the NP-polySA vaccine...
  12. ncbi request reprint Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate
    L M Krug
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 6:3493-8. 2000
    ..These studies will also quantitate the expression of genes controlling internalization (RFC-1) and polyglutamylation of PDX in tumor cells as correlates of response...
  13. doi request reprint Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer
    Lee M Krug
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
    J Thorac Oncol 6:384-6. 2011
    ....
  14. ncbi request reprint Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine
    Lee M Krug
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
    Lung Cancer 39:139-43. 2003
    ..In conclusion, bcl-2 and bax expression was similar in this population with advanced NSCLC to previously reported results for early stage disease, but did not predict response to vinorelbine plus docetaxel in this series...
  15. ncbi request reprint Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer
    V A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 18:1346-50. 2000
    ..We show that docetaxel (60 mg/m(2)) and vinorelbine (45 mg/m(2)) can be safely combined when given on an every 2-week schedule with filgrastim, with encouraging antitumor activity observed...
  16. ncbi request reprint Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin
    Lee M Krug
    Thoracic Oncology Service and Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 10:916-23. 2004
    ..In this clinical trial, we aimed to elicit an immune response against polysialic acid to target clinically inapparent residual disease in patients with SCLC who had successfully completed initial therapy...
  17. ncbi request reprint A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
    Daniel T Milton
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 107:1034-41. 2006
    ..The objective of this study was to determine the tolerability and efficacy of high-dose erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer (NSCLC)...
  18. doi request reprint Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy
    Vishal Gupta
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
    J Thorac Oncol 4:746-50. 2009
    ....
  19. ncbi request reprint Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy
    P O Livingston
    Department of Medicine, Clinical Immunology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 54:1018-25. 2005
    ..These findings support our plan to develop a tetravalent vaccine against SCLC targeting GM2, fucosyl GM1, globo H and polysialic acid...
  20. pmc A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies
    Paul K Paik
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Chemother Pharmacol 66:1079-85. 2010
    ....
  21. ncbi request reprint Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 21:2094-100. 2003
    ..This pilot trial combined gefitinib with carboplatin and paclitaxel to define the toxicities of the combination and assess drug-drug interactions in untreated advanced NSCLC patients...
  22. ncbi request reprint A phase I trial of perillyl alcohol in patients with advanced solid tumors
    Christopher G Azzoli
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Chemother Pharmacol 51:493-8. 2003
    ..This phase I trial was conducted to determine the optimal dose of perillyl alcohol...
  23. ncbi request reprint Surgery in the management of small cell lung cancer
    Robert J Downey
    Division of Thoracic Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 2:159-62. 2004
    ..However, a small number of patients present with resectable disease, and this review summarizes the available literature addressing the possible role for surgery in the treatment of these patients...
  24. ncbi request reprint A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors
    Matthew G Fury
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 57:671-7. 2006
    ..The aim of this phase I study was to determine the maximum-tolerated dose of pralatrexate when combined with probenecid given every 2 weeks in humans...
  25. pmc Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
    Peter G Maslak
    Leukemia Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Blood 116:171-9. 2010
    ..Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia...
  26. doi request reprint Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans
    Fan Liu
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, Columbia University, New York, New York
    J Thorac Oncol 5:879-84. 2010
    ....
  27. ncbi request reprint Trastuzumab in the treatment of non-small cell lung cancer
    Christopher G Azzoli
    Department of Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 29:59-65. 2002
    ..Whether trastuzumab will show a clear benefit for patients with NSCLC, either alone or in combination with established chemotherapy, remains to be proven in phase III testing...
  28. pmc The evolution of multimodality therapy for malignant pleural mesothelioma
    Marjorie G Zauderer
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Treat Options Oncol 12:163-72. 2011
    ..Clearly, MPM requires a multidisciplinary approach and, due to the myriad of open questions, much effort continues to focus on identifying the optimal combination of surgery, chemotherapy, and radiation...
  29. ncbi request reprint Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Clin Oncol 26:247-51. 2003
    ..Patients predisposed to peripheral edema from some other cause may be at increased risk for developing severe peripheral edema with gemcitabine...
  30. ncbi request reprint Targeting lethal minimal residual disease in small cell lung cancer
    Jyoti D Patel
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Oncol 30:79-85. 2003
    ..This review will focus on the detection of minimal residual disease as well as strategies with which to treat it, including matrix metalloproteinase inhibitors, tyrosine kinase inhibitors, and vaccine therapy...
  31. pmc A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 2:638-44. 2007
    ..We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer...
  32. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  33. ncbi request reprint Pulmonary neuroendocrine tumors: What (little) do we know?
    Lin Chi Chen
    Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Natl Compr Canc Netw 4:623-30. 2006
    ..This article discusses the current understanding of the epidemiology, pathologic characteristics, treatment, and prognosis of this spectrum of diseases...
  34. ncbi request reprint Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:1103-9. 2004
    ..Phase II trials suggested female sex and adenocarcinoma were associated with response. We undertook this analysis to identify additional clinical and pathologic features associated with sensitivity to gefitinib...
  35. doi request reprint Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer
    Lin Chi Chen
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Ave, New York, NY, United States
    Lung Cancer 67:216-20. 2010
    ..We conducted this study to determine if GD2/GM2 synthase RNA could be detected in SCLC cell lines and human tissues, and whether mRNA transcript levels corresponded with disease status...
  36. ncbi request reprint Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial
    Raja M Flores
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Thorac Oncol 1:289-95. 2006
    ..We designed this clinical trial to test the feasibility of induction chemotherapy followed by EPP and RT in locally advanced MPM with the ultimate aim of improving survival...
  37. ncbi request reprint A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:2692-8. 2007
    ..This phase 1 study was designed to determine the maximum tolerated dose and toxicity of pralatrexate plus paclitaxel or docetaxel in patients with advanced cancer...
  38. ncbi request reprint Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
    Daniel T Milton
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
    Cancer 110:599-605. 2007
    ..A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC)...
  39. doi request reprint Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials
    Paul K Paik
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 5:275-9. 2010
    ....
  40. pmc A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors
    Yelena Y Janjigian
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10065, USA
    Cancer Chemother Pharmacol 65:833-8. 2010
    ..We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor...
  41. ncbi request reprint Vaccine therapy for small cell lung cancer
    Lee M Krug
    Department of Medicine, Memorail Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Oncol 31:112-6. 2004
    ..To optimize an immune response against a broad range of tumor phenotypes, these components will be combined into a polyvalent vaccine. A randomized phase II trial of this polyvalent vaccine is planned to start in 2004...
  42. ncbi request reprint The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease
    Scott A Laurie
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 95:119-26. 2002
    ..The objective of this study was to document the natural history of second lung carcinomas, common second tumors that arise in survivors of Hodgkin disease (HD)...
  43. ncbi request reprint Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma
    Faye M Johnson
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer 106:366-74. 2006
    ..In the current study, the authors investigated the feasibility of combining these drugs in the treatment of patients with SCLC...